BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 23197725)

  • 1. Soluble aβ promotes wild-type tau pathology in vivo.
    Chabrier MA; Blurton-Jones M; Agazaryan AA; Nerhus JL; Martinez-Coria H; LaFerla FM
    J Neurosci; 2012 Nov; 32(48):17345-50. PubMed ID: 23197725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.
    Sherman MA; LaCroix M; Amar F; Larson ME; Forster C; Aguzzi A; Bennett DA; Ramsden M; Lesné SE
    J Neurosci; 2016 Sep; 36(37):9647-58. PubMed ID: 27629715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperphosphorylation of Tau induced by naturally secreted amyloid-β at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3β signaling pathway.
    Tokutake T; Kasuga K; Yajima R; Sekine Y; Tezuka T; Nishizawa M; Ikeuchi T
    J Biol Chem; 2012 Oct; 287(42):35222-35233. PubMed ID: 22910909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
    Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
    Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Familial Alzheimer's disease mutations at position 22 of the amyloid β-peptide sequence differentially affect synaptic loss, tau phosphorylation and neuronal cell death in an ex vivo system.
    Tackenberg C; Kulic L; Nitsch RM
    PLoS One; 2020; 15(9):e0239584. PubMed ID: 32966331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.
    Umeda T; Maekawa S; Kimura T; Takashima A; Tomiyama T; Mori H
    Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease.
    Manczak M; Reddy PH
    Hum Mol Genet; 2012 Dec; 21(23):5131-46. PubMed ID: 22926141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fyn knock-down increases Aβ, decreases phospho-tau, and worsens spatial learning in 3×Tg-AD mice.
    Minami SS; Clifford TG; Hoe HS; Matsuoka Y; Rebeck GW
    Neurobiol Aging; 2012 Apr; 33(4):825.e15-24. PubMed ID: 21741124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
    Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
    J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology.
    Oddo S; Caccamo A; Tran L; Lambert MP; Glabe CG; Klein WL; LaFerla FM
    J Biol Chem; 2006 Jan; 281(3):1599-604. PubMed ID: 16282321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model.
    Hurtado DE; Molina-Porcel L; Iba M; Aboagye AK; Paul SM; Trojanowski JQ; Lee VM
    Am J Pathol; 2010 Oct; 177(4):1977-88. PubMed ID: 20802182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau phosphorylation and tau mislocalization mediate soluble Aβ oligomer-induced AMPA glutamate receptor signaling deficits.
    Miller EC; Teravskis PJ; Dummer BW; Zhao X; Huganir RL; Liao D
    Eur J Neurosci; 2014 Apr; 39(7):1214-24. PubMed ID: 24713000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ.
    Ittner A; Asih PR; Tan ARP; Prikas E; Bertz J; Stefanoska K; Lin Y; Volkerling AM; Ke YD; Delerue F; Ittner LM
    Acta Neuropathol; 2020 Sep; 140(3):279-294. PubMed ID: 32725265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo.
    Tomiyama T; Matsuyama S; Iso H; Umeda T; Takuma H; Ohnishi K; Ishibashi K; Teraoka R; Sakama N; Yamashita T; Nishitsuji K; Ito K; Shimada H; Lambert MP; Klein WL; Mori H
    J Neurosci; 2010 Apr; 30(14):4845-56. PubMed ID: 20371804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Early Growth Response 1 in the Hippocampus Alleviates Neuropathology and Improves Cognition in an Alzheimer Model with Plaques and Tangles.
    Qin X; Wang Y; Paudel HK
    Am J Pathol; 2017 Aug; 187(8):1828-1847. PubMed ID: 28641077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Death-associated protein kinase 1 mediates Aβ42 aggregation-induced neuronal apoptosis and tau dysregulation in Alzheimer's disease.
    Zhang T; Xia Y; Hu L; Chen D; Gan CL; Wang L; Mei Y; Lan G; Shui X; Tian Y; Li R; Zhang M; Lee TH
    Int J Biol Sci; 2022; 18(2):693-706. PubMed ID: 35002518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic knockdown of brain-derived neurotrophic factor in 3xTg-AD mice does not alter Aβ or tau pathology.
    Castello NA; Green KN; LaFerla FM
    PLoS One; 2012; 7(8):e39566. PubMed ID: 22870188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology.
    Oddo S; Caccamo A; Tseng B; Cheng D; Vasilevko V; Cribbs DH; LaFerla FM
    J Neurosci; 2008 Nov; 28(47):12163-75. PubMed ID: 19020010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Aβ and tau pathology in transgenic mouse models of Alzheimer's disease.
    Shao CY; Mirra SS; Sait HB; Sacktor TC; Sigurdsson EM
    Acta Neuropathol; 2011 Sep; 122(3):285-92. PubMed ID: 21630115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.